Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Itaru Hashimoto

Showing results (91-100 of 128) with videos related to

Pageof 13
Sort By:
Journal of Personalized Medicine|June 28, 2023
Clinical Effect of the C-Reactive Protein to Serum Albumin Ratio in Patients with Metastatic Gastric or Gastroesophageal Junction Cancer Treated with Trifluridine/TipiracilItaru Hashimoto, Kazuki Kano, Shizune Onuma, et al.
Anticancer Research|November 4, 2021
Safety and Feasibility of Gastrectomy for Gastric Cancer in Patients Receiving Antiplatelet and/or Anticoagulation TreatmentToru Aoyama, Masato Nakazono, Kenki Segami, et al.
In Vivo (Athens, Greece)|June 23, 2022
Clinical Impact of Platelet-to-albumin Ratio on Esophageal Cancer Patients Who Receive Curative TreatmentToru Aoyama, Miwha Ju, Keisuke Komori, et al.
Anticancer Research|July 26, 2024
Preoperative Visceral-to-Subcutaneous Fat Ratio by Sex as a Predictor of Postoperative Survival in Patients With Gastric CancerItaru Hashimoto, Keisuke Komori, Shizune Onuma, et al.
In Vivo (Athens, Greece)|September 13, 2022
The Clinical Impact of Synchronous and Metachronous Other Primary Cancer in Gastric Cancer Patients Who Receive Curative TreatmentToru Aoyama, Miwha Ju, Keisuke Komori, et al.
In Vivo (Athens, Greece)|October 26, 2021
The Clinical Influence of the C-Reactive Protein-to-Albumin Ratio in Patients Who Received Curative Treatment for Gastric CancerToru Aoyama, Masato Nakazono, Kenki Segami, et al.
World Journal of Surgery|November 14, 2024
Prognostic impact of adipose tissue loss at 1 month after surgery in patients with gastric cancerItaru Hashimoto, Keisuke Komori, Shizune Onuma, et al.
Anticancer Research|May 29, 2023
Evaluation of Irinotecan and Trifluridine/Tipiracil as Fourth-line Treatments After Third-line Nivolumab for Advanced Gastric CancerKei Hayashi, Mitsuhiro Furuta, Kyoko Furusawa, et al.
Anticancer Research|October 26, 2022
The Clinical Impact of Other Primary Cancer in Patients Who Received Curative Treatment for Esophageal CancerToru Aoyama, Yukio Maezawa, Kentaro Hara, et al.
Anticancer Research|February 27, 2022
Prognostic Impact of Immune-related Adverse Events in Gastric Cancer Patients Treated With NivolumabHideaki Suematsu, Kazuki Kano, Takanobu Yamada, et al.
Pageof 13

Showing results (91-100 of 128) with videos related to

Sort By:
Pageof 13
Journal of Personalized Medicine|June 28, 2023
Clinical Effect of the C-Reactive Protein to Serum Albumin Ratio in Patients with Metastatic Gastric or Gastroesophageal Junction Cancer Treated with Trifluridine/TipiracilItaru Hashimoto, Kazuki Kano, Shizune Onuma, et al.
Anticancer Research|November 4, 2021
Safety and Feasibility of Gastrectomy for Gastric Cancer in Patients Receiving Antiplatelet and/or Anticoagulation TreatmentToru Aoyama, Masato Nakazono, Kenki Segami, et al.
In Vivo (Athens, Greece)|June 23, 2022
Clinical Impact of Platelet-to-albumin Ratio on Esophageal Cancer Patients Who Receive Curative TreatmentToru Aoyama, Miwha Ju, Keisuke Komori, et al.
Anticancer Research|July 26, 2024
Preoperative Visceral-to-Subcutaneous Fat Ratio by Sex as a Predictor of Postoperative Survival in Patients With Gastric CancerItaru Hashimoto, Keisuke Komori, Shizune Onuma, et al.
In Vivo (Athens, Greece)|September 13, 2022
The Clinical Impact of Synchronous and Metachronous Other Primary Cancer in Gastric Cancer Patients Who Receive Curative TreatmentToru Aoyama, Miwha Ju, Keisuke Komori, et al.
In Vivo (Athens, Greece)|October 26, 2021
The Clinical Influence of the C-Reactive Protein-to-Albumin Ratio in Patients Who Received Curative Treatment for Gastric CancerToru Aoyama, Masato Nakazono, Kenki Segami, et al.
World Journal of Surgery|November 14, 2024
Prognostic impact of adipose tissue loss at 1 month after surgery in patients with gastric cancerItaru Hashimoto, Keisuke Komori, Shizune Onuma, et al.
Anticancer Research|May 29, 2023
Evaluation of Irinotecan and Trifluridine/Tipiracil as Fourth-line Treatments After Third-line Nivolumab for Advanced Gastric CancerKei Hayashi, Mitsuhiro Furuta, Kyoko Furusawa, et al.
Anticancer Research|October 26, 2022
The Clinical Impact of Other Primary Cancer in Patients Who Received Curative Treatment for Esophageal CancerToru Aoyama, Yukio Maezawa, Kentaro Hara, et al.
Anticancer Research|February 27, 2022
Prognostic Impact of Immune-related Adverse Events in Gastric Cancer Patients Treated With NivolumabHideaki Suematsu, Kazuki Kano, Takanobu Yamada, et al.
Pageof 13